Al Herbish Abdullah S, Al Alwan Ibrahim, Al Mutair Angham, Al Twaim Abdulaziz, Al Agha Abdul-Moein, Deeb Asma, Abdul-Rasoul Majedah, El-Awwa Ahmed, Al Mushcab Suzan, Esmat Khaled
a Department of Pediatric Endocrinology, Al Habib Medical Group, PO Box 91877, Riyadh 11643, Saudi Arabia.
b College of Medicine, Kind Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Expert Rev Endocrinol Metab. 2014 Jul;9(4):319-325. doi: 10.1586/17446651.2014.921115. Epub 2014 May 16.
Over the last 20 years, recombinant human growth hormone (somatropin) has been the cornerstone of managing children with growth hormone deficiency (GHD). Although both international and national guidelines for growth hormone (GH) therapy exist, there is currently no consensus on the optimal use of GH therapy in Gulf Cooperation Council (GCC) countries. The goals of GH therapy are to normalize height during childhood, attain normal adult height and correct metabolic abnormalities related to GHD. However, extended use of GH >50 µg/kg/day may increase frequency of adverse events. Here, we report the proceedings from a meeting of nine GCC pediatric endocrinology experts, which took place in Beirut in November 2011. The meeting was also attended by three European counterparts and aimed to provide consensus on best practice in the management of children with GHD in the GCC based on current local medical and regulatory environments.
在过去20年里，重组人生长激素（生长激素）一直是治疗生长激素缺乏症（GHD）儿童的基石。尽管存在国际和国家层面的生长激素（GH）治疗指南，但目前海湾合作委员会（GCC）国家在GH治疗的最佳使用方面尚未达成共识。GH治疗的目标是在儿童期使身高正常化、达到正常成人身高并纠正与GHD相关的代谢异常。然而，GH使用剂量超过50µg/kg/天可能会增加不良事件的发生频率。在此，我们报告2011年11月在贝鲁特举行的一次由9位GCC儿科内分泌专家参加的会议的会议记录。三位欧洲同行也出席了此次会议，会议旨在根据当前当地的医疗和监管环境，就GCC地区GHD儿童管理的最佳实践达成共识。
